Top Markets
#1 Black Phoenix Black Phoenix +367.67%
#2 Islamic Coin Islamic Coin +158.19%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +55.07%
#5 Akedo Akedo +39.88%
#6 Acurast Acurast +35.75%
#7 BasedHype BasedHype +29.56%
#8 GoPlus Security GoPlus Security +21.76%
#9 Quantum Resistant Ledger Quantum Resistant Ledger +21.69%
#10 Cryptopia Cryptopia +21.42%
Coin of the day
Black Phoenix Black Phoenix
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Amarantus BioScience Holdings, Inc. Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings, Inc.

AMBS
Pozycja w akcjach #41184
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm,... Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine. The company's diagnostic pipeline includes the LymPro test, a blood-based diagnostic designed to detect Alzheimer's disease by analyzing lymphocyte proliferation, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying individuals with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug targeting both Levadopa-Induced Dyskinesia in Parkinson's patients and attention deficit hyperactivity disorders (ADHD). Additionally, they are developing a mesencephalic-astrocyte-derived neurotrophic factor (MANF) for treating conditions modeled in animals, such as retinitis pigmentosa and retinal artery occlusion. Amarantus also maintains several specialized platforms: NuroPro, a diagnostic platform dedicated to neurodegenerative diseases with an initial application in Parkinson's; BC-SeraPro, an oncology diagnostic platform specifically for breast cancer; and the PhenoGuard platform, designed for discovering new neurotrophic factors. Beyond these, the company is progressing with Engineered Skin Substitute (ESS), a cell therapy-based product for autologous skin replacement, currently in mid-stage clinical development for severe, life-threatening burns. The company has established a collaborative research and development agreement with both the U.S. Army Institute of Surgical Research and Rutgers University. Established in 2008, Amarantus BioScience Holdings, Inc., which previously operated as Amarantus Bioscience, Inc. until its name change in April 2013, is headquartered in New York, New York.
Cena akcji
$0.0001
Ostatnia synchronizacja: 2026-08-11
Kapitalizacja rynkowa
$36.84K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-66.67%
Kraj
US
Handel Amarantus BioScience Holdings, Inc. (AMBS)

Kategoria

Healthcare
Historia ceny akcji dla Amarantus BioScience Holdings, Inc. (AMBS)
Najwyższa cena zamknięcia: $0.00 dnia 2026-08-01

Najniższa cena zamknięcia: $0.00 dnia 2010-09-01
Historia cen akcji firmy Amarantus BioScience Holdings, Inc. od 2010 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 0.00%
2025 -45.33%
2024 -92.14%
2023 -34.21%
2022 -85.44%
2021 56.94%
2020 -54.01%
2019 -24.76%
2018 -77.87%
2017 235.71%
2016 -95.77%
2015 -94.85%
2014 -99.02%
2013 49,751,484,054.67%
2012 -60.30%
2011 3,461.02%
2010 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $524.82 32.56%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $872.59 34.95%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $746.26 9.13%
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 $1.08K -6.68%
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $260.84 17.08%
BE